Back to Market返回行情

HYPD Hyperion DeFi, Inc.

USHealthcare
$3.09-0.96%ClosedMarket Cap: $15.4M

As of 2026-07-10 16:00

Why HYPD matters now

Hyperion DeFi, Inc. (HYPD) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.09 with -0.96% on the session and $15.4M in market capitalization; recent performance reads 1-month +0.29% and YTD -3.09%.

The latest financial table shown here is Q1 2026, with revenue of $244.3K, net income of $8.8M, and EPS of $0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -474.1%.

The latest indexable market news headline is "Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $7.75; recent insider activity includes Jung Hyunsu filing P-Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.63

P/S

16.51

EV/EBITDA

-0.60

DCF Value

$-1.63

FCF Yield

-474.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

63.7%

Operating Margin

-2012.6%

Net Margin

-3163.0%

ROE

-63.5%

ROA

-47.1%

ROIC

-31.1%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$244.3K$8.8M$0.30
Q4 2025$496.2K$-39.8M$-6.29
FY 2025$813.5K$-45.3M$-9.40
Q3 2025$302.5K$6.6M$1.85

Analyst Ratings

Consensus

Buy

Target (Consensus)

$7.75

Target (Median)

$7.75

Target Range

$7.75 - $7.75

Strong Buy: 0Buy: 2Hold: 0Sell: 0Strong Sell: 0
Chardan CapitalBuy
2026-06-08
Chardan CapitalBuy
2026-03-27

Trading Activity

Insider Trades

Jung Hyunsudirector, officer: See Remarks
Buy2026-06-02
Jung Hyunsudirector, officer: See Remarks
Buy2026-06-02
Jung Hyunsudirector, officer: See Remarks
Buy2026-06-02
Jung Hyunsudirector, officer: See Remarks
Buy2026-06-02
Jung Hyunsudirector, officer: See Remarks
Sell2026-05-28

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

2.48

Operating from the United States, Hyperion DeFi, Inc. is a company undergoing a significant shift from its foundational work in ophthalmic drug-delivery, known as Optejet. Its current trajectory involves establishing itself as the inaugural U.S. firm on Nasdaq to hold a cryptocurrency treasury, predominantly denominated in HYPE tokens originating from the Hyperliquid blockchain. Furthermore, Hyperion DeFi oversees the "Kinetiq × Hyperion" validator, persists with its decentralized finance (DeFi) staking strategies, and continues to advance its Optejet UFD™ technology for ocular health.